•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript